Is there macituximab/magenex oral medication?

Currently, Margetuximab only has an intravenous infusion formulation, and an oral version has not yet been developed. This is mainly due to the molecular structure characteristics of monoclonal antibody drugs. They have large molecular weights, high protein stability requirements, and extremely low oral absorption rates. They are easily degraded by proteases in the gastrointestinal environment and are difficult to effectively enter the blood circulation through the digestive tract, thereby maintaining anti-tumor activity. In clinical practice, magituximab is administered intravenously and is usually used in combination with chemotherapy to ensure stable distribution of the drug and fully exert its anti-HER2 activity.

The technical challenges of developing oral antibody drugs are huge, as they need to overcome issues such as molecular stability, absorption barriers, and maintenance of blood drug concentrations. Currently, global anti HER2 drug research and development is mainly focused on cutting-edge research on intravenous infusion of monoclonal antibodies, oral small molecule tyrosine kinase inhibitors (TKI) and oral bispecific antibodies. Margetuximab belongs to the traditional monoclonal antibody category, and its targeting properties and optimized design of the Fc fragment are highly dependent on immune effects, so intravenous infusion is still the best way to ensure efficacy.

The guidelines emphasize that for patients with advanced or metastatic HER2-positive breast cancer, margetuximab should be administered intravenously in combination with chemotherapy rather than administered orally, which is also the current standard of treatment practice. If oral antibodies or oral drugs with similar mechanisms appear in the future, problems of absorption and activity maintenance will need to be solved, otherwise they will not be able to replace the existing intravenous infusion solution.

Therefore, it can be clearly stated that there is currently no oral medication of margituximab on the market. Patients and parents should mainly use intravenous infusion regimens and conduct treatment under the guidance of professional doctors to ensure efficacy and safety.

Reference materials:https://www.margenza.com/